IA
SMMT icon

IFP Advisors’s Summit Therapeutics SMMT Stock Holding History

IFP Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46K Hold
169
– – ﹤0.01% 4145
2026
Q1 		$3.2K Sell
169
-4,260
-96% -$68.9K ﹤0.01% 3772
2025
Q4 		$77.5K Hold
4,429
– – ﹤0.01% 1950
2025
Q3 		$91.5K Buy
4,429
+65
+1% +$1.58K ﹤0.01% 1736
2025
Q2 		$92.9K Buy
4,364
+4,264
+4,264% +$97.2K ﹤0.01% 1682
2025
Q1 		$1.93K Sell
100
-404
-80% -$8.11K ﹤0.01% 3155
2024
Q4 		$8.99K Buy
504
+4
+0.8% +$78 ﹤0.01% 2567
2024
Q3 		$10.9K Buy
+500
New +$6.99K ﹤0.01% 2386

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

IFP Advisors's SMMT Position: Q2 2026 in Review

IFP Advisors held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 169 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #4145.

IFP Advisors first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $92.9K in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • IFP Advisors held 169 shares of Summit Therapeutics worth $2.46K as of Q2 2026.
  • IFP Advisors left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4145 holding.
  • IFP Advisors first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • IFP Advisors's Summit Therapeutics position peaked at $92.9K in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.